Matthew Robinson
@pa4gps.bsky.social
A source of timely and evidence based Prescribing Advice for GPs and other clinicians
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for February 2026. This update advises clinicians that semaglutide (Wegovy®, Ozempic® and Rybelsus®) use has been associated with non-arteritic... https://www.prescriber.org.uk/?p=1884
February 9, 2026 at 7:39 AM
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for February 2026. This update advises clinicians that semaglutide (Wegovy®, Ozempic® and Rybelsus®) use has been associated with non-arteritic... https://www.prescriber.org.uk/?p=1884
During January 2026 Clinical Knowledge Summaries were published or updated in the following areas. Analgesia - mild-to-moderate pain Contraception - IUC Gilbert's syndrome Itch - widespread Obstructive sleep apnoea syndrome Platelets - abnormal counts and... https://www.prescriber.org.uk/?p=1883
February 3, 2026 at 8:05 AM
During January 2026 Clinical Knowledge Summaries were published or updated in the following areas. Analgesia - mild-to-moderate pain Contraception - IUC Gilbert's syndrome Itch - widespread Obstructive sleep apnoea syndrome Platelets - abnormal counts and... https://www.prescriber.org.uk/?p=1883
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a further Drug Safety Update article for January 2026. This update advises clinicians that the product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and... https://www.prescriber.org.uk/?p=1882
January 30, 2026 at 7:54 AM
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a further Drug Safety Update article for January 2026. This update advises clinicians that the product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and... https://www.prescriber.org.uk/?p=1882
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of January 2026. This month there are two guidelines that impact upon primary care. The Overweight and obesity management guideline has been... https://www.prescriber.org.uk/?p=1881
January 26, 2026 at 7:59 AM
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of January 2026. This month there are two guidelines that impact upon primary care. The Overweight and obesity management guideline has been... https://www.prescriber.org.uk/?p=1881
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Ciclosporin (Vevizye®) has been accepted for restricted use in the treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult... https://www.prescriber.org.uk/?p=1880
January 20, 2026 at 8:29 AM
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Ciclosporin (Vevizye®) has been accepted for restricted use in the treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult... https://www.prescriber.org.uk/?p=1880
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for January 2026. This update advises clinicians that the warnings in the product information and on packaging for gabapentin, pregabalin,... https://www.prescriber.org.uk/?p=1879
January 9, 2026 at 8:05 AM
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for January 2026. This update advises clinicians that the warnings in the product information and on packaging for gabapentin, pregabalin,... https://www.prescriber.org.uk/?p=1879
The College of Sexual and Reproductive Healthcare (CoSRH) has published UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) for 2025. This guidance provides robust and up-to-date evidence on when contraceptives can and cannot be safely used. This... https://www.prescriber.org.uk/?p=1878
December 31, 2025 at 8:10 AM
The College of Sexual and Reproductive Healthcare (CoSRH) has published UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) for 2025. This guidance provides robust and up-to-date evidence on when contraceptives can and cannot be safely used. This... https://www.prescriber.org.uk/?p=1878
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of December 2025. This month there are three guidelines that impact upon primary care. The Child maltreatment: when to suspect maltreatment in... https://www.prescriber.org.uk/?p=1877
December 29, 2025 at 8:49 AM
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of December 2025. This month there are three guidelines that impact upon primary care. The Child maltreatment: when to suspect maltreatment in... https://www.prescriber.org.uk/?p=1877
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a further Drug Safety Update article for December 2025. This update warns that there is a risk of patient harm arising through medication error during a transition period where the... https://www.prescriber.org.uk/?p=1876
December 18, 2025 at 9:05 AM
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a further Drug Safety Update article for December 2025. This update warns that there is a risk of patient harm arising through medication error during a transition period where the... https://www.prescriber.org.uk/?p=1876
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Progesterone vaginal capsules (Prometrium®) have been accepted for use in the prevention of miscarriage in women presenting with bleeding in the first... https://www.prescriber.org.uk/?p=1875
December 12, 2025 at 7:58 AM
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Progesterone vaginal capsules (Prometrium®) have been accepted for use in the prevention of miscarriage in women presenting with bleeding in the first... https://www.prescriber.org.uk/?p=1875
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for December 2025. This update advises that new warnings will be added to all mesalazine containing medicines warning of the very rare risk of... https://www.prescriber.org.uk/?p=1874
December 9, 2025 at 8:01 AM
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for December 2025. This update advises that new warnings will be added to all mesalazine containing medicines warning of the very rare risk of... https://www.prescriber.org.uk/?p=1874
During November 2025 Clinical Knowledge Summaries were published or updated in the following areas. Analgesia - mild-to-moderate pain Contraception - emergency Hyponatraemia Macular degeneration - age-related All of the topics have been reviewed and updated... https://www.prescriber.org.uk/?p=1873
December 3, 2025 at 8:04 AM
During November 2025 Clinical Knowledge Summaries were published or updated in the following areas. Analgesia - mild-to-moderate pain Contraception - emergency Hyponatraemia Macular degeneration - age-related All of the topics have been reviewed and updated... https://www.prescriber.org.uk/?p=1873
The manufacturer of semaglutide (Rybelsus®) tablets have introduced a reformulated version of the medication that has an increased bioavailability allowing for the strength to be approximately halved. In addition to the improved bioavailability, the... https://www.prescriber.org.uk/?p=1872
November 28, 2025 at 7:57 AM
The manufacturer of semaglutide (Rybelsus®) tablets have introduced a reformulated version of the medication that has an increased bioavailability allowing for the strength to be approximately halved. In addition to the improved bioavailability, the... https://www.prescriber.org.uk/?p=1872
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of November 2025. This month there are three guidelines that impact upon primary care. The Suspected sepsis in people aged 16 or over:... https://www.prescriber.org.uk/?p=1871
November 21, 2025 at 8:03 AM
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of November 2025. This month there are three guidelines that impact upon primary care. The Suspected sepsis in people aged 16 or over:... https://www.prescriber.org.uk/?p=1871
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Budesonide suppository (Budenofalk®) has been accepted for the short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum... https://www.prescriber.org.uk/?p=1870
November 12, 2025 at 8:04 AM
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Budesonide suppository (Budenofalk®) has been accepted for the short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum... https://www.prescriber.org.uk/?p=1870
A Medicines Supply Notification has been distributed by NHS England and the Department of Health and Social Care advising the exenatide (Bydureon®) 2mg/0.85ml prolonged-release suspension for injection pre-filled pen has been discontinued. The notification... https://www.prescriber.org.uk/?p=1869
November 6, 2025 at 8:38 AM
A Medicines Supply Notification has been distributed by NHS England and the Department of Health and Social Care advising the exenatide (Bydureon®) 2mg/0.85ml prolonged-release suspension for injection pre-filled pen has been discontinued. The notification... https://www.prescriber.org.uk/?p=1869
During October 2025 Clinical Knowledge Summaries were published or updated in the following areas. Anticoagulation - oral Contraception - progestogen-only methods Diabetes - type 1 Earwax HIV infection and AIDS Mental health in students Osgood-Schlatter... https://www.prescriber.org.uk/?p=1868
November 4, 2025 at 8:09 AM
During October 2025 Clinical Knowledge Summaries were published or updated in the following areas. Anticoagulation - oral Contraception - progestogen-only methods Diabetes - type 1 Earwax HIV infection and AIDS Mental health in students Osgood-Schlatter... https://www.prescriber.org.uk/?p=1868
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for October 2025. This update is a call to action to improve patient safety linked to #MedSafetyWeek. This is an annual campaign taking place from 3 to... https://www.prescriber.org.uk/?p=1867
October 24, 2025 at 8:21 AM
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for October 2025. This update is a call to action to improve patient safety linked to #MedSafetyWeek. This is an annual campaign taking place from 3 to... https://www.prescriber.org.uk/?p=1867
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of October 2025. This month there is one technology appraisal and one guideline that impact upon primary care. The Mirabegron for treating... https://www.prescriber.org.uk/?p=1866
October 20, 2025 at 8:49 AM
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of October 2025. This month there is one technology appraisal and one guideline that impact upon primary care. The Mirabegron for treating... https://www.prescriber.org.uk/?p=1866
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Linzagolix (Yselty®) has been accepted for use in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of... https://www.prescriber.org.uk/?p=1865
October 14, 2025 at 6:46 AM
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines. Linzagolix (Yselty®) has been accepted for use in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of... https://www.prescriber.org.uk/?p=1865
The Department of Health and Social Care has recently announced a change to the prescribing restrictions for antiviral medicines for influenza. The requirement that an notification be issued by the Chief Medical Officer has been removed. Prescribing of... https://www.prescriber.org.uk/?p=1864
October 9, 2025 at 7:08 AM
The Department of Health and Social Care has recently announced a change to the prescribing restrictions for antiviral medicines for influenza. The requirement that an notification be issued by the Chief Medical Officer has been removed. Prescribing of... https://www.prescriber.org.uk/?p=1864
During September 2025 Clinical Knowledge Summaries were published or updated in the following areas. Acute childhood limp Addison's disease Baker's cyst Constipation in children Glaucoma Multiple myeloma Tiredness/fatigue in adults All of the topics have... https://www.prescriber.org.uk/?p=1863
October 6, 2025 at 6:44 AM
During September 2025 Clinical Knowledge Summaries were published or updated in the following areas. Acute childhood limp Addison's disease Baker's cyst Constipation in children Glaucoma Multiple myeloma Tiredness/fatigue in adults All of the topics have... https://www.prescriber.org.uk/?p=1863
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of September 2025. This month there are two technology appraisals, five guidelines and two health technology evaluations that impact upon... https://www.prescriber.org.uk/?p=1862
September 26, 2025 at 6:41 AM
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of September 2025. This month there are two technology appraisals, five guidelines and two health technology evaluations that impact upon... https://www.prescriber.org.uk/?p=1862
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for September 2025. This update reminds and reassures patients and clinicians that there is no evidence that taking paracetamol during pregnancy causes... https://www.prescriber.org.uk/?p=1861
September 24, 2025 at 6:36 AM
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Drug Safety Update article for September 2025. This update reminds and reassures patients and clinicians that there is no evidence that taking paracetamol during pregnancy causes... https://www.prescriber.org.uk/?p=1861
The manufacturer of Levemir® (insulin detemir) has announced a decision to discontinue this product in both the pre-filled pens (FlexPen) and cartridges with supplies expected to exhausted by the end of 2026. The Specialist Pharmacy Service offers more... https://www.prescriber.org.uk/?p=1860
September 8, 2025 at 7:02 AM
The manufacturer of Levemir® (insulin detemir) has announced a decision to discontinue this product in both the pre-filled pens (FlexPen) and cartridges with supplies expected to exhausted by the end of 2026. The Specialist Pharmacy Service offers more... https://www.prescriber.org.uk/?p=1860